London, UK, 3 March 2026 – Vidac Pharma Holdings Plc. (XETRA: T9G | ISIN: GB00BM9XQ619 | WKN: A3DTUQ) announces that the Company presented results from a compassionate use case involving its lead drug candidate, VDA-1102, at the Eilat Symposium on Pediatric Cancer.
The case involved a four-year-old girl diagnosed with recurrent ependymoma who was approaching a third brain surgery. A specific formulation of VDA-1102 was administered under compassionate use prior to surgery and continued for one month following surgery, with the aim of stabilizing the tumor’s hyper-glycolytic metabolism and modulating the tumor microenvironment ahead of subsequent surgical and radiotherapy intervention.
Treatment consisted of daily subcutaneous administration at a dose of approximately 10 mg/kg body weight. The patient subsequently underwent surgery and radiotherapy, both of which were reported as successful.
Data presented at the symposium indicated stabilization of metabolic markers, including lactate and lactate dehydrogenase (LDH) levels, during treatment. Analysis of the excised tumor tissue demonstrated measurable levels of VDA-1102 (approximately 100 ng/g), and plasma analysis indicated detectable levels of the compound for more than 12 hours following administration.
The patient, now six years old, is reported to have a significantly improved quality of life, with no observed cognitive impairment. Observations shared at the conference suggested that metabolic stabilization may have supported the overall therapeutic course.
During the symposium, Prof. Cyril Cohen of Bar-Ilan University highlighted the biochemical importance of Hexokinase-2 (HK2) in cancer metabolism, reinforcing the growing scientific recognition of HK2 as a central driver in tumor progression. International experts at the meeting emphasized the importance of targeting the tumor microenvironment, particularly in brain cancers, where a persistently hyperglycemic environment contributes to disease development and therapeutic resistance.
VDA-1102 is designed to target the Hexokinase-2 metabolic checkpoint, which is overexpressed and mislocalized in cancer cells. By dissociating HK2 from the mitochondrial membrane, the compound is intended to disrupt cancer-specific hyperglycolysis, restore apoptotic signaling pathways, and renormalize the tumor microenvironment.
Dr. Max Herzberg, Chairman and Chief Executive Officer of Vidac Pharma, stated:
“We are encouraged to see increasing scientific recognition of the central role of HK2 in cancer biology. For many years, research focused predominantly on HK1. Today, there is a growing understanding that overexpression of HK2 in cancer cells plays a critical role in blocking apoptosis and driving hyperglycolysis. By dissociating HK2 from the mitochondria, our drug candidates are designed to reverse this pathological process and renormalize cellular metabolism.”
The Company notes that this report relates to a single compassionate use case. Further clinical investigation will be required to evaluate safety and efficacy in controlled clinical studies involving larger patient populations.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding clinical development plans, study objectives, regulatory pathways, and potential future trials. Forward-looking statements are based on current expectations, assumptions, and information available to the Company at the time of publication and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, clinical trial outcomes, patient recruitment, regulatory review and approval processes, intellectual property matters, financing needs, and general market conditions. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.
For more information, please contact:
Vidac Pharma Holdings Plc
Dr. Max Herzberg
20–22 Wenlock Road
London N1 7GU
United Kingdom
https://www.vidacpharma.com
investors@vidacpharma.com
About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines for oncologic and onco-dermatologic diseases. The Company develops therapeutic candidates designed to modify the hyper-glycolytic tumor microenvironment by targeting the overexpression and mislocalization of the Hexokinase-2 (HK2) metabolic checkpoint in cancer cells, with the aim of renormalizing cellular metabolism and selectively inducing programmed cell death without affecting surrounding normal tissue.
Vidac’s lead drug candidate, VDA-1102, has previously demonstrated activity in clinical studies in Actinic Keratosis (AK) and Cutaneous T-cell Lymphoma (CTCL).